Boston Expects Synergy To Dominate Drug-Eluting Stents In US
This article was originally published in Clinica
Executive Summary
Boston Scientific Corp. is putting a lot of faith in its Synergy stent to dominate the US drug-eluting market – a device that was only recently approved by FDA to treat coronary artery disease.
You may also be interested in...
FDA Approves Boston Scientific’s SYNERGY BP Stent For High Bleeding Risk Patients
The bioabsorbable polymer-coated, sirolimus-eluting stent is the first drug-eluting stent approved for this population.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.